The present case report describes the treatment of a 12-year-old boy who had skeletal Class III malocclusion with concave facial profile, hypodivergent facial pattern with anterior cross bite and deep overbite. The treatment plan included rapid palatal expansion with maxillary protraction and fixed edgewise appliance. The results show that anterior cross bite was corrected and facial esthetics greatly improved after about two years of treatment.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Screening for Structural Heart Defects: A Single-Center Retrospective Cost Analysis for Fetal Echocardiography in Adults with Congenital Heart Disease.
Pediatr Cardiol
January 2025
Department of Pediatric Cardiology, Seattle Children's Hospital, Seattle, WA, USA.
Fetal echocardiography (FE) is recommended for parents with congenital heart disease (pCHD) due to a 3-6% recurrence risk of congenital heart disease (CHD). This study aimed to evaluate the cost of FE for detecting neonatal CHD in pCHD. FE data were collected between 12/2015 and 12/2022.
View Article and Find Full Text PDFWeTICA: A directed search weighted ensemble based enhanced sampling method to estimate rare event kinetics in a reduced dimensional space.
J Chem Phys
January 2025
Department of Chemical and Biological Sciences, S. N. Bose National Centre for Basic Sciences, Block-JD, Sector-III, Salt Lake, Kolkata 700106, India.
Estimating rare event kinetics from molecular dynamics simulations is a non-trivial task despite the great advances in enhanced sampling methods. Weighted Ensemble (WE) simulation, a special class of enhanced sampling techniques, offers a way to directly calculate kinetic rate constants from biased trajectories without the need to modify the underlying energy landscape using bias potentials. Conventional WE algorithms use different binning schemes to partition the collective variable (CV) space separating the two metastable states of interest.
View Article and Find Full Text PDFPulmonary Arterial Hypertension in a Patient With a Lung Mass: Any Link?
Cureus
December 2024
Pulmonology, King Abdulaziz Medical City, Jeddah, SAU.
A 52-year-old female patient with a history of atrial septal defect repair presented with progressive dyspnea and echocardiographic findings suggestive of pulmonary hypertension (PH). Incidentally, a lung mass was discovered on computed tomography (CT). Initial evaluation revealed World Health Organization functional class III symptoms and significant weight loss.
View Article and Find Full Text PDFThe SIRT5-JIP4 interaction promotes osteoclastogenesis by modulating RANKL-induced signaling transduction.
Cell Commun Signal
January 2025
Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, 197 Ruijin Road II, Shanghai, 200025, China.
Receptor activator of nuclear factor kappa-B ligand (RANKL) initiates a complex signaling cascade that is crucial for inducing osteoclast differentiation and activation. RANKL-induced signaling has been analyzed in detail, and the involvement of TNF receptor-associated factor 6 (TRAF6), calmodulin-dependent protein kinase (CaMK), NF-κB, mitogen-activated protein kinase (MAPK), activator protein-1 (AP-1), and molecules that contain an immunoreceptor tyrosine-based activation motif (ITAM) has been reported. However, the precise molecular steps that regulate RANKL signaling remain largely unknown.
View Article and Find Full Text PDFSafety and efficacy of the ROCK-2-inhibitor Belumosudil in cGvHD treatment - a retrospective, German-Swiss multicenter real-world data analysis.
Bone Marrow Transplant
January 2025
Department of Internal Medicine III, University Hospital Regensburg, Regensburg, Germany.
Belumosudil is a first in class ROCK2-inhibitor approved by the FDA for the 3rd line treatment of chronic graft-versus-host disease (cGvHD). In this retrospective real-world analysis, we report safety and efficacy data of belumosudil treatment from 5 German/Swiss transplant centers. A total of 33 adult patients (median age 59 years) with moderate (n = 2) or severe (n = 31) cGvHD were treated on individual request due to lack of EMA approval.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!